Confronto

KPV vs. Thymosin Alpha-1

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Guarigione

N. CAS

67727-97-3

62304-98-7

Peso molecolare

342.4 g/mol

3108.32 g/mol

Emivita

nessun dato

2 h

Sequenza

KPV

Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN

Meccanismo d'azione

KPV

KPV is the C-terminal fragment of α-melanocyte-stimulating hormone (α-MSH). In preclinical models the inflammation-modulating activity is attributed predominantly to inhibition of the NF-κB and MAP-kinase signalling pathways, accompanied by reduced release of pro-inflammatory mediators. Cellular uptake via the peptide transporter PepT1 has also been described. The precise molecular mechanisms are not conclusively understood and not confirmed in humans.

Thymosin Alpha-1

Thymosin Alpha-1 is an N-terminally acetylated peptide originally isolated from the thymus. It modulates T-lymphocyte maturation and function and acts on dendritic cells via Toll-like receptors (TLR9 / TLR2). In preclinical and some clinical studies, increased interferon-gamma responses and altered T-cell subpopulations have been reported.

Base di evidenze

Evidenza più alta

Modello animale

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	KPV	Thymosin Alpha-1
Germania	Non approvato	Non approvato
IT	—	Su prescrizione
Stati Uniti	Solo ricerca	Non approvato

Voci complete

Frequently asked questions

What is the difference between KPV and Thymosin Alpha-1?: KPV is classified as "Guarigione", while Thymosin Alpha-1 is classified as "Guarigione". KPV: KPV is the C-terminal tripeptide (lysine-proline-valine) of the hormone α-MSH, corresponding to its positions 11–13. In cell and rodent models an inflammation-modulating activity has been described, primarily via inhibition of the NF-κB signalling pathway. The evidence is drawn almost exclusively from preclinical work (cell culture and mouse); controlled human studies are essentially absent. KPV is not an approved medicinal product. Thymosin Alpha-1: Synthetic 28-amino-acid peptide identical to a naturally occurring thymus peptide. Approved as Zadaxin in more than 30 countries (not US/EU) for hepatitis B treatment and as an immunomodulator. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, KPV or Thymosin Alpha-1?: The highest available evidence level is "Modello animale" for KPV and "RCT sull'uomo" for Thymosin Alpha-1. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of KPV and Thymosin Alpha-1 in Germany and the United States?: Germania: KPV — Non approvato, Thymosin Alpha-1 — Non approvato. Stati Uniti: KPV — Solo ricerca, Thymosin Alpha-1 — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

KPV

Thymosin Alpha-1

Germania

Non approvato

—

Su prescrizione

Stati Uniti

Solo ricerca

Non approvato

Frequently asked questions

What is the difference between KPV and Thymosin Alpha-1?

KPV is classified as "Guarigione", while Thymosin Alpha-1 is classified as "Guarigione". KPV: KPV is the C-terminal tripeptide (lysine-proline-valine) of the hormone α-MSH, corresponding to its positions 11–13. In cell and rodent models an inflammation-modulating activity has been described, primarily via inhibition of the NF-κB signalling pathway. The evidence is drawn almost exclusively from preclinical work (cell culture and mouse); controlled human studies are essentially absent. KPV is not an approved medicinal product. Thymosin Alpha-1: Synthetic 28-amino-acid peptide identical to a naturally occurring thymus peptide. Approved as Zadaxin in more than 30 countries (not US/EU) for hepatitis B treatment and as an immunomodulator. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, KPV or Thymosin Alpha-1?

The highest available evidence level is "Modello animale" for KPV and "RCT sull'uomo" for Thymosin Alpha-1. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of KPV and Thymosin Alpha-1 in Germany and the United States?

Germania: KPV — Non approvato, Thymosin Alpha-1 — Non approvato. Stati Uniti: KPV — Solo ricerca, Thymosin Alpha-1 — Non approvato. These are factual summaries with source and review date on the individual pages.